Ameliorative effect of SA4503, a novel cognitive enhancer, on the basal forebrain lesion-induced impairment of the spatial learning performance in rats

Pharmacology Biochemistry and Behavior

Volumn 59, Issue 1, 1998, Pages 129-134

  Senda, Toshihiko ^a   Matsuno, Kiyoshi ^a   Kobayashi, Tetsuya ^a   Nakazawa, Minako ^a   Nakata, Katsuhiko ^a   Mita, Shiro ^a  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Basal forebrain (BF) lesion; Morris water maze (MWM) task; Rats; SA4503; Spatial learning performance

Indexed keywords

1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE; NOOTROPIC AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; CHOLINERGIC NERVE; CONTROLLED STUDY; DRUG EFFECT; FOREBRAIN; LEARNING; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL ORIENTATION;

ANIMALS; CORPUS STRIATUM; HIPPOCAMPUS; LEARNING DISORDERS; MALE; MAZE LEARNING; NOOTROPIC AGENTS; PIPERAZINES; PROSENCEPHALON; PSYCHOMOTOR PERFORMANCE; RATS; RATS, INBRED F344; RECEPTORS, SIGMA;

ANIMALIA;

EID: 0031983090     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00385-7     Document Type: Article

References (40)

1. Anger W. K. Animal test system to study behavioral dysfunctions of neurodegenerative disorders. Neurotoxicology. 12:1991;403-414.
2. Bartus R. T., Dean R. L. III, Beer B., Lippa A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-417.
3. Bartus R. T., Flicker C., Dean R. L., Pontecorvo M., Figueiredo J. C., Fisher S. K. Selective memory loss following nucleus basalis lesions. Long term behavioral recovery despite persistent cholinergic deficiencies Pharmacol. Biochem. Behav. 23:1985;125-135.
4. Becker R. Therapy of the cognitive deficit in Alzheimer's disease. The cholinergic system Becker R., Giacobini E. Cholinergic basis for Alzheimer therapy. 1991;1-22 Birkhauser, Boston.
5. Bowen D. M., Allen S. J., Benton J. S., Goodhardt M. J., Haan E. A., Palmer A. M., Sims N. R., Smith C. C. T., Spillane J. A., Esiri M. M., Neary D., Snowdon J. S., Wilcock G. K., Davison A. N. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J. Neurochem. 41:1983;266-272.
6. Brouwers P., Cox C., Martin A., Chase T., Fedio P. Differential perceptual-spatial impairment in Huntington's and Alzheimer's dementias. Arch. Neurol. 41:1984;1073-1076.
7. Collerton D. Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience. 19:1986;1-28.
8. Coyle J. T., Price D. L., DeLong M. R. Alzheimer's disease. A disorder of cortical cholinergic innervation Science. 219:1983;1184-1190.
9. DeNoble V. J., DeNoble K. F., Spencer K. R., Johnson L. C., Cook L., Myers M. J., Scribner R. M. Comparison of Dup 996, with physostigmine, THA and 3,4-DAP on hypoxia-induced amnesia in rats. Pharmacol. Biochem. Behav. 36:1990;957-961.
10. Etienne P., Robitaille Y., Wood P., Gauthier S., Nair N. P. V., Quirion R. Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease. Neuroscience. 19:1986;1279-1291.
11. Flicker C., Dean R. L., Watkins D. L., Fisher S. K., Bartus R. T. Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the rat. Pharmacol. Biochem. Behav. 18:1983;973-981.
12. Flood J. F., Cherkin A. Scopolamine effects on memory retention in mice. A model of dementia? Behav. Neural. Biol. 45:1986;169-184.
13. 3H]DOPA in various regions of the brain. J. Neurochem. 13:1966;655-669.
14. Gottfries C. G. Alzheimer's disease and senile dementia. Biochemical characteristics and aspects of treatment Psychopharmacology (Berlin). 86:1985;245-252.
15. Henderson V. W., Mack W., Williams B. W. Spatial disorientation in Alzheimer's disease. Arch. Neurol. 46:1989;391-394.
16. Itzhak Y. Multiple sigma binding sites in the brain. Itzhak Y. Sigma receptors. 1994;113-137 Academic Press Inc, San Diego.
17. 3H]acetylcholine release from rat hippocampal slices. Eur. J. Pharmacol. 200:1991;343-345.
18. 1 receptor agonist, in the rat brain. J. Pharmacol. Exp. Ther. 279:1996;106-113.
19. Kwo-On-Yuen P. F., Mandel R., Chen A. D., Thal L. J. Tetrahydroaminoacridine improves the spatial acquisition deficit produced by nucleus basalis lesions in rats. Exp. Neurol. 108:1990;221-228.
20. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
21. Mandel R. J., Thal L. J. Physostigmine improves water maze performance following nucleus basalis magnocellularis lesions in rats. Psychopharmacology (Berlin). 96:1988;421-425.
22. Matsuno K., Matsunaga K., Mita S. Increase of extracellular acetylcholine level in rat frontal cortex induced by (+)N-allylnormetazocine as measured by brain microdialysis. Brain Res. 575:1992;315-319.
23. Matsuno K., Matsunaga K., Senda T., Mita S. Increase in extracellular acetylcholine level by sigma ligands in rat frontal cortex. J. Pharmacol. Exp. Ther. 265:1993;851-859.
24. Matsuno K., Senda T., Matsunaga K., Mita S. Ameliorating effects of σ receptor ligands on the impairment of passive avoidance tasks in mice. Involvement in the central cholinergic system Eur. J. Pharmacol. 261:1994;43-51.
25. 1 receptor in (+)-N-allylnormetazocine-stimulated hippocampal cholinergic functions in rats. Brain Res. 690:1995;200-206.
26. 1 receptor agonist. Eur. J. Pharmacol. 306:1996;271-279.
27. 1 receptor agonistic properties, Behav. Brain Res. 83:1997;221-224.
28. Miyamoto M., Kato J., Narumi S., Nagaoka A. Characteristics of memory impairment following lesioning of the basal forebrain and medial septal nucleus in rats. Brain Res. 419:1987;19-31.
29. Morris R. G. M. Spatial localization does not require the presence of local cues. Learn. Motiv. 12:1981;239-260.
30. Nabeshima T., Ogawa S., Nishimura H., Fuji K., Kameyama T., Sasaki Y. Staurosporine facilitates recovery from the basal forebrain-lesion-induced impairment of learning and deficit of cholinergic neuron in rats. J. Pharmacol. Exp. Ther. 257:1991;562-566.
31. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 2:1986;Academic Press, New York.
32. Reisberg B., Ferris S. H., De Leon M. J., Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am. J. Psychiatry. 139:1982;1136-1139.
33. 1 receptor agonist, on memory impairment induced by cholinergic dysfunction in rats. Eur. J. Pharmacol. 315:1996;1-10.
34. Senda T., Matsuno K., Kobayashi T., Mita S. Reduction of the scopolamine-induced impairment of passive avoidance performance by σ receptor agonist in mice. Physiol. Behav. 61:1997;257-264.
35. Shinoda M., Matsuo A., Toide K. Pharmacological studies of a novel prolyl endopeptidase inhibitor, JTP-4819, in rats with middle cerebral artery occlusion. Eur. J. Pharmacol. 305:1996;31-38.
36. Summers W. K., Viesselman J. O., Marsh G. M., Candelora K. Use of THA in treatment of Alzheimer-like dementia. Pilot study in twelve patients Biol. Psychiatry. 16:1981;145-153.
37. Summers W. K., Majovski L. V., Marsh G. M., Tachki K., Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N. Engl. J. Med. 315:1986;1241-1245.
38. Wanibuchi F., Nishida T., Yamashita H., Hidaka K., Koshiya K., Tsukamoto S., Usuda S. Characterization of a novel muscarinic receptor agonist, YM796. Comparison with cholinesterase inhibitors in in vivo pharmacological studies Eur. J. Pharmacol. 265:1994;151-158.
39. Yamazaki M., Matsuoka N., Maeda N., Kuratani K., Ohkubo Y., Yamaguchi I. FR121196, a potential antidementia drug, ameliorates the impaired memory of rat in the Morris water maze. J. Pharmacol. Exp. Ther. 272:1995;256-263.
40. Yoshida S., Suzuki N. Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in rats. Eur. J. Pharmacol. 250:1993;117-124.